ArticleClinical immunology (Orlando, Fla.)2021
Genetic justification of severe COVID-19 using a rigorous algorithm.
Article in Clinical immunology (Orlando, Fla.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Genetic polymorphisms associated with susceptibility to COVID-19 disease and severity: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Predicting long-term outcomes in intracerebral hemorrhage: a comparative study of machine learning models highlights the prognostic value of hematoma clearance.Frontiers in neurology · 2026Article
- Common Genetic Variants in Rare Disorders: Hematology and Beyond.Current issues in molecular biology · 2025Article
- Correlation between Genomic Variants and Worldwide COVID-19 Epidemiology.Journal of personalized medicine · 2024Article
- Artificial intelligence for diagnosis of mild-moderate COVID-19 using haematological markers.Annals of medicine · 2023Article
- Multi-omic Profiling Reveals Early Immunological Indicators for Identifying COVID-19 Progressors.bioRxiv : the preprint server for biology · 2023Article
- Advanced Tree-Based Techniques for Predicting Unconfined Compressive Strength of Rock Material Employing Non-Destructive and Petrographic Tests.Materials (Basel, Switzerland) · 2023Article
- Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know.Immunobiology · 2023Review
- Targeted genotyping of COVID-19 patients reveals a signature of complement C3 and factor B coding SNPs associated with severe infection.Immunobiology · 2023Article
- Hybridizing five neural-metaheuristic paradigms to predict the pillar stress in bord and pillar method.Frontiers in public health · 2023Article
- Dataset of single nucleotide polymorphisms of immune-associated genes in patients with SARS-CoV-2 infection.PloS one · 2023Article
- Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: A review.World journal of experimental medicine · 2022Review
- Targeted Genotyping of MIS-C Patients Reveals a Potential Alternative Pathway Mediated Complement Dysregulation during COVID-19 Infection.Current issues in molecular biology · 2022Article
- Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls.Journal of clinical medicine · 2022Article
- Long-term outcomes of pediatric infections: from traditional infectious diseases to long Covid.Future microbiology · 2022Review
- Complement dysregulation is associated with severe COVID-19 illness.Haematologica · 2022Article
- Genetic prediction of ICU hospitalization and mortality in COVID-19 patients using artificial neural networks.Journal of cellular and molecular medicine · 2022Article
- Activation of Complement Components on Circulating Blood Monocytes From COVID-19 Patients.Frontiers in immunology · 2022Article
- Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study.Frontiers in medicine · 2022Article
- Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 9 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies suggest excessive complement activation in severe coronavirus disease-19 (COVID-19). The latter shares common characteristics with complement-mediated thrombotic microangiopathy (TMA). We hypothesized that genetic susceptibility would be evident in patients with severe COVID-19 (similar to TMA) and associated with disease severity. We analyzed genetic and clinical data from 97 patients hospitalized for COVID-19. Through targeted next-generation-sequencing we found an ADAMTS13 variant in 49 patients, along with two risk factor variants (C3, 21 patients; CFH,34 patients). 31 (32%) patients had a combination of these, which was independently associated with ICU hospitalization (p = 0.022). Analysis of almost infinite variant combinations showed that patients with rs1042580 in thrombomodulin and without rs800292 in complement factor H did not require ICU hospitalization. We also observed gender differences in ADAMTS13 and complement-related variants. In light of encouraging results by complement inhibitors, our study highlights a patient population that might benefit from early initiation of specific treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.